Italy’s health regulator is reportedly seeking damages worth nearly$2 billion from three of the world’s largest pharmaceutical firms for their repeated antitrust violations and subsequent harm on the nation’s health industry.
According to reports, the nation’s health ministry announced Wednesday it is seeking about $1.6 billion in damages from Novartis and Roche for anticompetitive action taken between 2012 and 2014; it wants another $19 million from Pfizer.
In its statement, the regulator cited various antitrust rulings against the pharmaceutical firms that lead to “considerable damage” imposed on Italy’s health service.
The announcement follows two months after the nation’s antirust regulator found Roche and Novartis of striking an unfair pay-for-delay deal, which saw Novartis pay Roche to prevent the release of a less expensive drug. The companies were fined $254.2 million.
The companies denied any wrongdoing and said they plan to appeal the decision.
Italy’s highest administrative court ruled last February that Pfizer abused its marked dominance regarding another drug.
The violations are now the reason health officials are calling for the companies to pay up, claiming the harm done to competition by the alleged behavior has lead to harm to national healthcare.
Full content: Business Recorder
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI